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Abstract
Glucocorticoids are widely used for the suppression of inflammation, but evidence 
is growing that they can have rapid, non-genomic actions that have been unappreci-
ated. Diverse cell signaling effects have been reported for glucocorticoids, leading us 
to hypothesize that glucocorticoids alone can swiftly increase the 3′,5′-cyclic adeno-
sine monophosphate (cAMP) production. We found that prednisone, fluticasone, 
budesonide, and progesterone each increased cAMP levels within 3  minutes with-
out phosphodiesterase inhibitors by measuring real-time cAMP dynamics using the 
cAMP difference detector in situ assay in a variety of immortalized cell lines and pri-
mary human airway smooth muscle (HASM) cells. A membrane- impermeable glu-
cocorticoid showed similarly rapid stimulation of cAMP, implying that responses are 
initiated at the cell surface. siRNA knockdown of Gαs virtually eliminated glucocorticoid- 
stimulated cAMP responses, suggesting that these drugs activate the cAMP production 
via a G protein-coupled receptor. Estradiol had small effects on cAMP levels but G protein 
estrogen receptor antagonists had little effect on responses to any of the glucocorticoids 
tested. The genomic and non-genomic actions of budesonide were analyzed by RNA-Seq 
analysis of 24 hours treated HASM, with and without knockdown of Gαs. A 140-gene 
budesonide signature was identified, of which 48 genes represent a non-genomic signa-
ture that requires Gαs signaling. Collectively, this non-genomic cAMP signaling modality 
contributes to one-third of the gene expression changes induced by glucocorticoid treat-
ment and shifts the view of how this important class of drugs exerts its effects.
K E Y W O R D S
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1 |  INTRODUCTION
Glucocorticoids are used in the treatment of a wide array of dis-
eases, including rheumatoid arthritis, autoimmune disorders, 
allergy, cancer, and respiratory syndromes. The occurrence of 
side effects and glucocorticoid resistance, particularly with 
systemic use, greatly hamper their use.1 The combination of 
glucocorticoids ß-agonists has long been considered the most 
effective means for controlling asthma and chronic obstruc-
tive pulmonary disease, even more than using either alone.2-5  
While the mechanisms underlying glucocorticoid genomic 
effects on enhancing the clinical efficacy of ß-agonist have 
been previously studied,6 the possibility that non-genomic 
signaling by glucocorticoids enhance the clinical efficacy of 
ß-agonists has not been investigated due to the limited tools 
to measure real time kinetics of intracellular changes in 3′,5′- 
cyclic adenosine monophosphate (cAMP) concentration.
Conventional thought suggests that glucocorticoids alter 
the cell function through changes in the gene expression that 
occur via activation of ubiquitously expressed intracellular glu-
cocorticoid receptors (GR).7 In the absence of glucocorticoid, 
the GR resides in the cytoplasm then translocates to the cell 
nucleus upon binding of ligand. Nuclear GR then interacts with 
glucocorticoid response elements (GREs) to alter the gene ex-
pression. Various reports, some published over 25 years ago, 
suggest that glucocorticoids also induce rapid alterations in 
various signaling processes that appear to be non-genomic in 
nature.5,8,9 The human skin blanching assay (often called the 
vasoconstrictor assay) has been used for nearly 50 years as a 
means of qualitatively assessing the topical availability and 
potency of glucocorticoids.10 This test characterizes the po-
tency of glucocorticoids through non-genomic effects on va-
soconstriction. Some of these non-genomic effects may require 
specific interactions with membrane-bound versions of GR 
(mGR) or other undefined membrane components.5 Short du-
ration treatment of various cell types with glucocorticoid affect 
many different signaling events, including agonist-induced cal-
cium release, reactive oxygen species, and arachidonic acid re-
lease.11-16 BSA-conjugated cortisol, a steroid unable to cross the 
cell membrane, has been used as a tool to differentiate plasma 
membrane GR effects from those of the cytosolic GR. For in-
stance, the effects of short (5 to 90 minutes) exposure of BSA-
cortisol on leukemia cells was studied using proteomic tools 
and 128 unique proteins were found to be specifically upreg-
ulated.17 Interestingly, the putative mGR may interact with the 
NMDA receptor or may directly activate a G protein-coupled 
receptor (GPCR) coupled to Gαs and/or Gq/11.18 While these and 
other studies support the idea that glucocorticoids possess the 
ability to modulate rapid, non-genomic signaling, none reveal 
the specific signaling pathways or receptor(s) responsible.
Our studies demonstrate that glucocorticoids rapidly in-
crease the cAMP levels in a variety of cell types. In human 
airway smooth muscle (HASM) glucocorticoids trigger this 
non-genomic signaling via binding to an extracellular site and 
activating the stimulatory G protein, Gαs. While a GPCR might 
be involved, our data suggest that the G protein estrogen receptor 
(GPER) does not mediate this response. Removal of this rapid, 
non-genomic signal via siRNA knockdown of Gαs modifies the 
transcriptomic response to the glucocorticoid, budesonide. Out 
of a 140 gene budesonide signature, the alteration of 48 of these 
genes was dependent upon the Gαs-cAMP signal. Thus, of all 
the canonical changes in gene transcription by glucocorticoid, 
a full one-third of them require this rapid, non-genomic signal.
2 |  MATERIALS AND METHODS
2.1 | Materials
Forskolin (Fsk) was purchased from LC Laboratories. Cell 
culture media and components were purchased from Thermo 
Fisher. Fetal bovine serum was purchased from Atlanta 
Biologicals. siRNA construct for silencing GNAS were 
obtained from Dharmacon. The sense sequence used was 
CGAUGUGACUGCCAUCAUCUU. Secondary antibod-
ies were obtained from Santa Cruz Biotechnology. All other 
drugs and chemicals were purchased from Sigma-Aldrich un-
less otherwise noted.
2.2 | Cell culture
HASM cells were isolated from deceased, de-identified lung do-
nors by enzymatic dissociation in accordance with Institutional 
Review Board approval and as described previously.19 HASM 
cells were grown in Ham's F-12 media (Thermo Fisher 
Scientific) supplemented with 10% fetal bovine serum, pen/
strep, 25 mM HEPES, 1.7 mM CaCl2, and l-glutamine. Cells 
were kept at 5% CO2 and 37°C. Experiments were performed 
on cells from passage 3-7 using cells from 10 different donors 
in total, and at least three different donors for each study. Patient 
demographics are described in Table 1. Human fetal lung 
(HFL-1) fibroblasts (American Type Culture Collection) were 
grown in Ham's F12 medium with 10% fetal bovine serum and 
1% antibiotic-antimycotic solution. HEK-293 cells (American 
Type Culture Collection) were cultured in Dulbecco's modified 
Eagle's medium (Thermo Fisher Scientific) supplemented with 
10% fetal bovine serum. All cells were kept in a humidified 
incubator with 5% CO2 at 37°C.
2.3 | Transfection
To transfect HASM cells with siRNA, 250  000 cells were 
incubated with 100  nM siRNA (target or scrambled) for 
30 minutes at room temperature using HiPerFect transfection 
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reagent (Qiagen) following the manufacturer's instructions. 
Cells were then transferred to 6-well plates. After 5  hours 
incubation at 37°C with 5% CO2, HASM growth media con-
taining 5% fetal bovine serum was added for 48 hours. Media 
was replaced with serum-free media for 24  hours prior to 
drug treatment or assay.
2.4 | cADDis cAMP assays
We performed kinetic measurements of cAMP production in 
live cells using the green cAMP difference detector in situ 
(cADDis) cAMP sensor (Montana Molecular, Bozeman, 
MT) as described previously.20 Briefly, sub-confluent 
HASM, HFL-1, or HEK-293 cells were plated on a black-
walled, clear flat bottom 96-well plates along with recombi-
nant BacMam virus expressing the cADDis sensor and 1 µM 
trichostatin-A. Cells were grown overnight at 5% CO2 and 
37°C. Media was aspirated and replaced with 180  µL per 
well of 1X Dulbecco's Phosphate Buffered Saline Solution 
without calcium and magnesium. The 96-well plate was cov-
ered with aluminum foil and incubated at room temperature 
for 30  minutes. Cell fluorescence was read from the plate 
bottom using excitation/emission wavelengths of 494 and 
522  nm, respectively, using a SpectraMax M5 plate reader 
(Molecular Devices). A 5 minutes kinetic read on unstimu-
lated cells was monitored until the variability in each well's 
fluorescence was ≤5%. Cells were then stimulated with the 
indicated drug and fluorescence changes in each well were 
read at 30 seconds intervals for 30 minutes. Data were trans-
formed to the change in fluorescence over the initial fluo-
rescence (ΔF/F0) then plotted and fit to a single site decay 
model using GraphPad Prism 8.0 (GraphPad Software). The 
K value (slope) and the plateau from this one-site decay fit 
are reported. To create a concentration-response curve, the K 
was multiplied by the plateau for each drug concentration and 
plotted on a log scale.
2.5 | Immunoblot analysis
Whole cell lysates were obtained by scraping cells in modi-
fied RIPA lysis buffer (50  mM Tris–HCl, pH 7.5, 150  mM 
NaCl, 1% Igepal CA-630, plus mammalian protease inhibi-
tor cocktail). Whole cell lysates were separated on 10% SDS-
polyacrylamide gels by electrophoresis before being transferred 
to PVDF membranes (Millipore) by electroblotting. ß-actin 
(Santa Cruz Biotechnology sc-47778, 1:1000 dilution) and Gαs 
(Santa Cruz Biotechnology sc-135914, 1:500 dilution) antibod-
ies were simultaneously incubated overnight at 4°C following 
block in nonfat milk. The appropriate secondary antibodies 
with conjugated horseradish peroxidase were purchased from 
Santa Cruz Biotechnology. Images were captured using a 
BioRad Gel Doc system then the alignment, exposure, and 
contrast of each image was optimized using Adobe Photoshop 
CS4. Immunoreactive bands were analyzed by densitometric 
analysis using the volume plus density method and normalized 
to ß-actin, as described previously.21
2.6 | RNA-Seq
Control or Gαs-knockdown HASM cells (see transfection 
procedure above) from six different donors (see Table 1) at 
the same passage number were treated with either vehicle 
or 1 µM budesonide for 24 hours. Total RNA was extracted 
using the miRNAeasy mini kit (Qiagen). Approximately 
1 µg of RNA from each sample was used to generate RNA-
Seq cDNA libraries for sequencing using the TruSeq RNA 
Sample Prep Kit v2 (Illumina, Inc). Sequencing of 100 bp 
single-end reads was performed with an Illumina HiSeq 4000 
instrument at the University of California, Irvine Genomics 
High-Throughput Facility.
2.7 | Data analysis and statistics
1. Data analysis and statistics: Standard curves were fit 
and unknown values were extrapolated using GraphPad 
Prism 8.0. Data were presented as the mean  ±  SEM. 
Statistical comparisons (t tests and one-way analysis of 
variance) were performed and graphics were generated 
using GraphPad Prism 8.0.
2. RNA-Seq alignment and quantification: RNA-Seq data 
quality was checked using FastQC and all samples had 
high quality score (Phred score >28) for all nucleotides 
T A B L E  1  HASM cell patient demographics
Designation Age Sex Race
N100217 39 M Black
N041717 19 M Caucasian
N021014 54 M Caucasian
N101317K 54 F Hispanic
N012317 29 F Caucasian
N012414 20 F Black
N030116 69 M Caucasian
N062017 47 M Hispanic
N080817 23 M Black
N012518K 18 M Caucasian
N112017K 53 M Asian
N011118K 14 M Caucasian
Notes: HASM cells were derived from the following patients who had no history 
of asthma or chronic illness. RNA-seq analysis was performed using the cell 
lines from the first six rows.
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sequenced. FastQC analysis showed Illumina TrueSeq 
adapters were overrepresented in two samples. Cutadapt 
software was used to remove the identified adapters and 
reads were filtered for a minimum length of 20 bp. The 
Rsubread R package (version v1.30.6; Liao et al22) was 
used to align the reads and to produce the gene-level 
summarized values using hg38 annotation from the 
Rsubread package. Integer-based gene counts were gen-
erated using the featureCounts function in the Rsubread 
package.22,23 limma24 and edgeR (version v3.22.3) 25,26 ) 
packages were used to calculate FPKM values27 and a cus-
tom script to convert FPKM to TPM values.28 Ensembl 
Genome Reference Consortium Human Build 38 patch 
12 (GRCh38.p12) database was used to convert gene IDs 
to Hugo Gene Nomenclature Commitee (HGNC) HCNC 
gene symbols.29 RNA-Seq data was available in GEO 
under accession number GSE13 0715. GSE94335, an in-
dependent dataset including 34 samples from fatal-asthma 
and non-asthma donors treated with control and budeso-
nide,40 was also processed with the same alignment and 
quantification pipeline to minimize technical and analyti-
cal bias.
3. Differential gene expression and pathway analysis: Genes 
with less than 100 counts in 50% of our samples were filtered 
out prior to any analysis. Principal Component Analysis 
(PCA) was used to investigate interpatient variability com-
pared to treatment-specific variability. The prcromp func-
tion from the stats R package was used to compute PCAs. 
Plotting of first two PCAs showed intended treatment-spe-
cific variability was more dominant than interpatient vari-
ability. Therefore, no adjustment was necessary.
4. DESeq2 R package was used to generate differen-
tial gene-lists between various treatment conditions: 
(a) vehicle-treated and Gαs-knockdown vehicle-treated 
HASM cells, (b) budesonide-treated and Gαs-knockdown 
budesonide-treated HASM cells, (c) vehicle-treated and 
budesonide-treated HASM cells, and (d) Gαs-knockdown 
vehicle-treated and Gαs-knockdown budesonide-treated 
HASM cells. Gene-lists from (a) and (b) were used for 
in silico validation of Gαs (GNAS gene) knockdown. 
Differential gene-lists from (c) and (d) represent the bude-
sonide induced transcriptional activity in control (genomic 
+ non-genomic) and Gαs-knockdown  (genomic only) 
HASM cells, respectively. (c) and (d) were compared to 
previously published budesonide-associated differen-
tially expressed genes by Himes et al30 for validation of 
our budesonide signature (Figure S1). Overlap analysis 
of signature gene-lists was performed using a Venn dia-
gram. Then, ASSIGN, a pathway profiling toolkit, was 
used to evaluate the gene-lists (c) and (d) in predicting 
budesonide-induced transcriptional activity in HASM.31 
(c) and (d) gene-lists were budesonide signatures due to 
Gαs-independent and -dependent transcriptional changes 
due to 24-hour post-budesonide treatment, respectively. 
An independent HASM dataset, GSE94335,40 was used 
to validate both budesonide signatures. Predicted bude-
sonide activity was correlated using Pearson’s correlation 
to evaluate budesonide and budesonide-Gαs knockdown 
signatures.
5. Gene set enrichment analysis: Using fgsea function, a 
gene set enrichment analyses were performed against 
KEGG molecular pathways and gene ontology gene an-
notations for both budesonide signatures. Cutoff values of 
P < .05 and a false discovery rate (FDR) < 0.05 were used 
to assess significant enrichment.
6. Analysis of budesonide transcriptional activity in publicly 
available data: Connectivity scores (CSs) were assessed 
using the gene-list that was unique to differentially ex-
pressed gene- list (3) using a ConnectivityMap (CMAP) 
query to identify most similar and dissimilar perturbagen 
signatures in a publicly available database.32
All RNA-Seq data analyses except the CMAP query were 
performed in R version 3.6.0 and Bioconductor version 3.733 
(R Core Team, 2014; http://www.R-proje ct.org/). All codes 
are available at https ://github.com/mumta hena/gluc_HASMs .
3 |  RESULTS
3.1 | Rapid effect of glucocorticoids on 
cellular production of cAMP
Since glucocorticoids have been found to rapidly activate 
different signaling pathways in neurons,9,18 we hypothesized 
that glucocorticoids stimulate the cAMP production in mam-
malian cells. Using a highly sensitive cAMP biosensor ca-
pable of displaying rapid cAMP kinetics in live HEK-293 
cells (cADDis, Montana Molecular), we examined responses 
to two commonly prescribed glucocorticoids. As shown 
in Figure 1A, the addition of 10  µM fluticasone increased 
cAMP levels (reflected as a decay in cADDis fluorescence) 
within 30-60 seconds of drug exposure. This cAMP response 
reached a plateau at approximately 12 minutes and the maxi-
mal effect was nearly as efficacious as the response to a maxi-
mal concentration of the direct adenylyl cyclase activator, Fsk 
(10 µM, Figure 1A). A 10-fold lower concentration of flutica-
sone (1 µM) also stimulated the cAMP levels, but at a some-
what slower rate of decay and smaller plateau. Fluticasone 
concentrations lower than 1 µM induced responses that were 
not statistically significant when compared to vehicle control 
(0.1 µM fluticasone is shown). The addition of budesonide 
(0.1, 1, or 10 µM) elicited responses similar to fluticasone 
(Figure 1B). We also expressed the cADDis sensor in HFL-1 
cells, a human fetal lung fibroblast cell line, and measured 
cAMP responses to glucocorticoids. Both budesonide and 
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fluticasone induced rapid increases in cAMP levels in HFL-1 
cells that were similar to that seen in HEK-293 cells (10 µM 
budesonide plateau was −0.251 in HFL-1 cells compared to 
−0.395 in HEK-293 cells; 10  µM fluticasone plateau was 
−0.341 in HFL-1 cells compared −0.457 in HEK-293 cells). 
Thus, two different glucocorticoids induce rapid increases in 
cAMP levels in two different cell lines (HEK-293 and HFL-1 
cells) and these responses were large enough to observe with-
out the presence of phosphodiesterase (PDE) inhibitors.
When primary cultured HASM cells obtained from sev-
eral donors were treated with various glucocorticoids, a rapid 
production of cAMP was again observed. Prednisone (Figure 
2A), fluticasone (Figure 2C), and budesonide (Figure 2D) 
elicited cAMP responses in HASM within minutes of drug 
addition. Prednisone induced smaller responses than flutica-
sone or budesonide, but significantly increased cAMP within 
8 minutes of treatment. We also examined other steroids and 
found that progesterone (Figure 2B) stimulated the cAMP 
production in HASM cells. Estradiol did not stimulate the 
cAMP responses that were significantly different than ve-
hicle (Figure 4A). To determine if glucocorticoids increase 
cAMP via inhibition of PDEs, we preincubated HASM with a 
broad-spectrum PDE inhibitor, 3-isobutyl-1-methylxanthine 
(IBMX). Fluticasone retained cAMP stimulating activity in 
the presence of 10 µM IBMX (Figure 2E). IBMX stimulated 
cADDis responses on its own, so once the baseline was set 
following IBMX addition, the maximal response to Fsk was 
diminished as compared to control (shown in Figure 2C). All 
these responses occurred within minutes of drug addition, in-
dicating a non-genomic mode of action.
We have recently observed that this non-genomic action 
of glucocorticoids in HASM is blocked by RU486 but not 
altered by knockdown of GRα.34 Therefore, we posited that 
this rapid stimulation of cAMP levels involves glucocorticoid 
F I G U R E  1  Glucocorticoids stimulate 
rapid cAMP responses in HEK-293 cells. 
Cells were incubated with recombinant 
BacMam virus expressing the cADDis 
cAMP sensor. After establishing baseline, 
fluorescence decay was monitored for 
30 minutes after addition of drug. cADDis 
sensor fluorescent decay curves elicited 
by 1 or 10 µM fluticasone (A) 1 or 10 µM 
budesonide (B) are shown. Fluorescence 
decay curves elicited by vehicle and 10 µM 
forskolin are shown as reference to the 
minimal and maximal responses. Each 
point represents the mean ± SEM of n = 5 
experiments and lines represent the fit by 
one-phase decay non-linear regression 
analysis. * denotes P < .05 for the 1 µM 
glucocorticoid conditions at the indicated 
time points, # denotes P < .05 for the 10 µM 
glucocorticoid conditions at the indicated 
time points compared to vehicle using 
multiple t tests and the Holm-Sidak method 
for correction of multiple comparisons. The 
0.1 µM glucocorticoid conditions were not 
significantly different than vehicle
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binding to a plasma membrane receptor. Addition of 10 µM 
cortisol or 10 µM cortisol-BSA conjugate (the latter drug is 
unable to cross cell membranes) elicited identical cAMP re-
sponses in HASM (Figure 2F). Cortisol and cortisol-BSA in-
duced significant reductions in cADDis fluorescence within 
4 minutes (as compared to vehicle) and reached a maximal re-
sponse that was about half of that induced by a near-maximal 
concentration of Fsk (1 µM). These data were consistent with 
the idea that glucocorticoids activate a membrane-bound re-
ceptor via an outward-facing binding site to stimulate cAMP 
production.
3.2 | Role of Gαs in mediating glucocorticoid 
effects on production of cAMP
Since the stimulation of cAMP by glucocorticoids is rapid 
and plasma membrane delimited, we hypothesized that the 
response involves the direct activation of the stimulatory G 
protein, Gαs. To this end, we used siRNA strategy to knock-
down the expression of Gαs in HASM cells. HASM cells were 
transfected with validated siRNA sequences specific for GNAS 
or scrambled siRNA.35 As shown in Figure 3A, immunoblot 
F I G U R E  2  Glucocorticoids stimulate rapid cAMP responses in HASM. Primary HASM cells were incubated with recombinant BacMam 
virus expressing the cADDis cAMP sensor. After establishing baseline, fluorescence decay was monitored for 30 minutes after addition of drug. 
cADDis sensor fluorescent decay curves elicited by 1 or 10 µM prednisone (A), 1 or 10 µM progesterone (B), 1 or 10 µM fluticasone (C), 1 or 
10 µM budesonide (D), and 1 or 10 µM fluticasone in cell preincubated with 10 µM IBMX (E). Fluorescence decay curves elicited by 10 µM 
forskolin are shown in each panel as reference to the maximal response. Fluorescence decay by cADDis was monitored for 30 minutes after 
addition of either vehicle, 1 µM forskolin, 10 µM cortisol, or 10 µM cortisol-BSA (F). A different Y axis scale is used on panel E to better visualize 
these responses. Each point represents the mean ± SEM of n = 4-6 donors and lines represent the fit by one-phase decay non-linear regression 
analysis. * denotes P < .05, ** denotes P < .01 of each time point compared to vehicle using multiple t tests and the Holm-Sidak method for 
correction of multiple comparisons
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analysis indicated a reduction in expression of both the long and 
short forms of Gαs in siRNA transfected HASM as compared 
to scrambled control. We consistently observed a reduction in 
the cADDis sensor expression levels following the transfection 
procedure, which resulted in the maximal cADDis responses 
being reduced by about 50% (comparing the response to 10 µM 
Fsk in Figure 2 vs Figure 3). cAMP responses to vehicle or Fsk 
(10  µM) were unaffected by Gαs knockdown, indicating that 
adenylyl cyclase expression and total activity were unaffected 
(Figure 3B). In contrast, cAMP responses to 100 nM formoterol 
(a long-acting ß2-adrenoceptor agonist approved for the treat-
ment of asthma) were significantly reduced in Gαs-knockdown 
HASM as compared to control, consistent with ß-adrenoceptors 
stimulating cAMP production via activation of Gαs (Figure 3C). 
cAMP responses to budesonide (10 µM, Figure 3D) or flutica-
sone (10 µM, Figure 3E) were also significantly diminished in 
cells with Gαs knockdown. Taken together, these results indi-
cate that glucocorticoids activate a rapid, non-genomic signal-
ing pathway that stimulates Gαs and the production of cAMP.
3.3 | Role of GPER in mediating 
glucocorticoid effects on production of cAMP
Given that glucocorticoids act via an extracellular binding 
site and depend upon Gαs, we hypothesize that a GPCR is 
involved. The GPER is a known GPCR that is activated by 
specific steroids and has been reported to couple to Gαs in 
certain cells.36-39 1 and 10  µM estradiol stimulated small 
cAMP responses that were not significantly different than 
vehicle (Figure 4A). GPER mRNA is detected in a wide 
array of cell types, including HEK-293, HFL-1, and HASM 
cells (GEO accession numbers GSE12 8076, GSE73555, and 
GSE52778). We examined budesonide cAMP responses in 
cells preincubated with selective GPER antagonists to de-
termine if glucocorticoids stimulated cAMP via activation 
of GPER. In HASM cells, the addition of 1  µM G36 had 
no effect on fluticasone stimulation of cAMP responses 
(Figure 4B). Another GPER antagonist, G15 (1  µM), also 
had no effect on fluticasone responses (Figure 4C). These 
F I G U R E  3  Glucocorticoid stimulation of cAMP depends upon Gαs expression. A, HASM were transfected with siRNA specific for GNAS 
or scrambled control for 48 hours and lysates analyzed by SDS-PAGE and immunoblotting simultaneously with antibodies specific for Gαs and 
ß-actin. Image is representative of n = 3 experiments on separate donor cells. RNA sequencing revealed GNAS transcript was reduced 6.07 ± 0.35 
fold (n = 6) following transfection with siRNA. B-E, cADDis sensor was expressed in control or Gαs-knockdown HASM using a recombinant 
BacMam virus then responses to vehicle, forskolin (C), formoterol (C), budesonide (D), or fluticasone (E) were measured. Each point represents the 
mean ± SEM of n = 4-5 donors. * denotes P < .05, ** denotes P < .01 of each time point
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results are consistent with the idea that the GPER is not in-
volved in mediating the rapid cAMP signaling stimulated by 
glucocorticoids.
3.4 | Transcriptional effects of glucocorticoid 
non-genomic signaling through Gαs
Glucocorticoid effects on cells are attributed to their genomic 
actions, so the role that this rapid, non-genomic signal plays 
in regulating cell function is relatively under studied.5 To in-
vestigate the transcriptional effects of the non-genomic sign-
aling through Gαs, we performed an RNA-Seq analysis from 
HASM cells treated with 1 µM budesonide, comparing tran-
scripts from control and Gαs-knockdown samples 24 hours 
post-treatment. We used HASM cell lines isolated from six 
different donors at the same passage. Each donor cell line was 
subjected to four conditions: scrambled siRNA treated with 
vehicle, scrambled siRNA treated with 1  µM budesonide, 
GNAS siRNA treated with vehicle, GNAS siRNA treated 
with 1 µM budesonide. We chose a 24-hour drug treatment 
duration in order to capture the classical genomic effects of 
glucocorticoids. We chose to use 1 µM budesonide since this 
concentration elicited a sub-maximal cAMP response that 
could be completely abolished by Gαs knockdown. In addi-
tion, this lower concentration is more consistent with other 
studies of the genomic effects of glucocorticoid treatment. 
With this approach, any observed differences in the bude-
sonide transcriptomes between control and Gαs-knockdown 
cells would reflect the role of the non-genomic glucocorti-
coid signaling. We performed quantitative analysis of the 
transcripts that were altered by budesonide acting through 
both genomic and non-genomic signaling (control) or acting 
through only genomic signaling (Gαs knockdown).
We began our analysis with the hypothesis that the non-ge-
nomic transcriptional activities are due to signaling via Gαs. 
Two novel budesonide signatures were generated using the 
differential gene expression lists: (a) a 140-gene genomic and 
non-genomic signature of budesonide effect in control cells, and 
(b) a 121-gene genomic only signature of budesonide in Gαs-
knockdown cells (Figure 5; Supplemental Tables S1 and S2). 
ASSIGN, a pathway analysis toolkit, was used to assess the 
predictive ability of these gene-sets in determining budesonide 
induced transcriptional activity. As an internal validation, we 
used the signatures to predict budesonide activity in all 24 
HASM samples using ASSIGN. Predictions show that both 
signatures were able to correctly identify budesonide induced 
transcriptional activity in all 24 HASM samples (Pearson's 
correlation 0.9977; P < .0001; Supplemental Figure S4). To 
validate these signatures further, we applied these two sig-
natures to a previously published independent dataset of 34 
HASM samples derived from asthma and non-asthma donors 
with either control or budesonide treatment40 (GEO dataset 
accession GSE94335). Since there are variation in budesonide 
F I G U R E  4  GPER antagonists do 
not block glucocorticoid-stimulated cAMP 
responses. Primary HASM cells were 
incubated with recombinant BacMam virus 
expressing the cADDis cAMP sensor. After 
establishing baseline, fluorescence decay 
was monitored for 30 minutes after addition 
of drug. cADDis sensor fluorescent decay 
curves elicited by 1 or 10 µM estradiol (A) 
or 10 µM fluticasone (C). A different Y axis 
scale is used on panel A to better visualize 
these responses. Each point represents the 
mean ± SEM of n = 5 donors and lines 
represent the fit by one-phase decay non-
linear regression analysis. No significant 
differences are seen comparing fluticasone 
alone to either condition where a GPER 
antagonist (G15 or G36) was included at 
any time point using multiple t tests and 
the Holm-Sidak method for correction of 
multiple comparisons
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concentration and duration for the treatment conditions be-
tween the datasets (100 nM for 1 hour vs 1 µM for 24 hours of 
budesonide treatment), we used ASSIGN’s background adap-
tive feature. Thus, the background gene expression differences 
between our signature (training) and GSE94335 (test) samples 
were adjusted to provide more accurate prediction. Despite the 
slight difference in predicted genomic + non-genomic and ge-
nomic only budesonide activity, both signatures accurately esti-
mated high budesonide activity in budesonide-treated HASMs 
derived from both asthma and non-asthma donors (Pearson's 
correlation 0.9995; P  <  .0001, Supplemental  Table S1).40 
This similarity in predicted budesonide activity validates the 
F I G U R E  5  The transcriptional activity due to budesonide treatment in HASM. A, 140 gene budesonide signature representing the 
transcriptional activity (genomic + non-genomic) variation between control and budesonide treated HASM. B, 121 gene budesonide Gαs 
knockdown signature showing the transcriptional activity (genomic only) variation between Gαs knockdown-control and budesonide-treated 
HASM. For both (A) and (B), each row represents a gene, and each column represents a sample. The red cell color represents level of 
overexpression and the blue cell color represents levels of low expression. Brighter the red, higher the gene expression and darker the blue, lower 
the expression. C, Comparison of genes from each budesonide signatures show 94 genes were shared between budesonide (out of 140 genes) and 
budesonide-Gαs knockdown (out of 121 genes) signatures. 48 genes unique to budesonide signature represent Gαs dependent activity
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robustness of both types of budesonide signatures in capturing 
transcriptional activity regardless of Gαs status 24 hours post-
budesonide treatment. Although genes within each signature 
are different, the ubiquitous effects of the canonical genomic 
signaling pathway activated by budesonide, along with a large 
number of genes in the signatures, maintains the robustness of 
the predictive ability.
To evaluate the roles of these signature genes in known cel-
lular processes, a gene set enrichment analysis was performed 
with databases, particularly, Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways and Gene Ontology (GO) 
annotations.41 These databases provide curated gene-sets for 
understanding the functions and utilities of biological systems, 
cellular components, and molecular functions of a given test 
gene-set. There was no significant enrichment of any KEGG 
or GO gene-sets for the budesonide signature gene-lists after 
adjusting the p-value for multiple comparisons. This implies 
that these budesonide signatures present unique transcriptional 
activity not represented by the gene-sets in these databases.
Next, we analyzed the overlapping genes from the two 
budesonide signatures to evaluate the genomic and non- 
genomic interplay of these signature genes. There were 92 genes 
shared between budesonide and budesonide Gαs-knockdown 
signatures (Figure 5C). Forty-eight genes were unique to the 
budesonide signature, indicating these genes (26 upregu-
lated and 22 downregulated) are dependent on Gαs-dependent 
budesonide transcriptional activity (Table 2,Supplemental 
Figure S2). We then used an unsupervised hierarchical clus-
tering method to investigate how the transcriptional activity 
attributed to this non-genomic signature affected the HASM 
without knowing the treatment conditions. Essentially, we 
evaluated these 48 genes in their ability to differentiate the 
treatment conditions. The hierarchical clustering clearly dif-
ferentiates the two budesonide treatment conditions (Table 2, 
Figure S2). The clustering also shows two distinct sub-clusters 
that identify the non-genomic signature.
To find similar patterns of non-genomic transcriptional 
activity in existing data sets, a gene expression query was per-
formed using these 48 genes in the CMAP database. CMAP 
is a publicly available independent dataset housing over one 
million differential gene expression signatures. A CMAP 
query is used to find similarities and dissimilarities across 
the curated expression profiles of various perturbations, in-
cluding compounds, overexpressions, and knockdowns.32 CS 
is a quantitative score between a query gene-list and a per-
turbagen that ranges from −100 (opposing signature) to 100 
(same signature). CS from a query with 48 Gαs-dependent 
budesonide induced gene-list across the CMAP database was 
the highest (98.97) for “GR agonist” among the 171 phar-
macologic classes available in the CMAP database. CSs for 
GR agonists including budesonide investigated in differ-
ent cell lines including prostate (PC3), melanoma (A375), 
lung (A549), and hepatocellular cancer (HA1E, HCC515) 
T A B L E  2  List of 48 genes representing the non-genomic 
budesonide transcriptional activity in HASM cells
Gene symbols Gene name
ADARB1 adenosine deaminase, RNA-specific, B1
ADH1B alcohol dehydrogenase 1B (class I), beta 
polypeptide
ANGPTL1 angiopoietin-like 1
APBB2 amyloid beta (A4) precursor protein-binding, fam-
ily B, member 2
ARID5A AT rich interactive domain 5A (MRF1-like)
ARMC8 armadillo repeat containing 8
ARNTL aryl hydrocarbon receptor nuclear translocator-like
CCDC102B coiled-coil domain containing 102B
CCND3 cyclin D3
CHST7 carbohydrate (N-acetylglucosamine 6-O) sul-
fotransferase 7
CIART Circadian Associated Repressor of Transcription
FADS1 fatty acid desaturase 1
FSTL3 follistatin-like 3 (secreted glycoprotein)
GAL galanin prepropeptide
GPR1 G protein-coupled receptor 1
HMGA1 high mobility group AT-hook 1
IER5L immediate early response 5-like
IL16 interleukin 16
LY96 lymphocyte antigen 96
MAP3K7CL NAMAP3K7 C-Terminal Like
MEX3B mex-3 homolog B (C. elegans)
MMD monocyte to macrophage 
differentiation-associated
NNMT nicotinamide N-methyltransferase
NR1D1 nuclear receptor subfamily 1, group D, member 1
NR1D2 nuclear receptor subfamily 1, group D, member 2
NRG1 neuregulin 1
PDE5A phosphodiesterase 5A, cGMP-specific
PDLIM1 PDZ and LIM domain 1
PER1 period homolog 1 (Drosophila)
PKDCC protein kinase domain containing, cytoplasmic 
homolog (mouse)
PLA2G4A phospholipase A2, group IVA (cytosolic, 
calcium-dependent)
PLXNA2 plexin A2
PRRX1 paired related homeobox 1
PTPRG protein tyrosine phosphatase, receptor type, G
PTX3 pentraxin 3, long
RAB7B RAB7B, member RAS oncogene family
RGMB RGM domain family, member B
SEMA3A sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3A
(Continues)
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show high similarity (CSs>90) (Supplemental  Figure S3, 
Table S2). This high  similarity across various cell lines 
and glucocorticoid agonists indicates that the non-genomic 
budesonide signature, as represented by these 48 genes, ex-
tends beyond HASM and is significantly associated with the 
GR agonists including, but not limited to, budesonide.
4 |  DISCUSSION
A number of glucocorticoids cause rapid increases in cAMP 
levels in multiple cell types (Figures 1 and 2). These responses 
appear to be mediated by a plasma membrane-associated re-
ceptor with an outward facing binding site since albumin-
conjugated cortisol, which can't cross the plasma membrane, 
retains activity (Figure 2F). The increase in cAMP levels re-
quires stimulation of Gαs, as knockdown of GNAS via siRNA 
drastically reduces cAMP signaling by glucocorticoids. 
Since our cAMP assays are performed in the absence of PDE 
inhibitors there is a possibility that glucocorticoids could 
work via inhibition of PDE activity. However, inclusion of a 
broad spectrum PDE inhibitor did not impinge upon flutica-
sone responses, implying that the glucocorticoid works inde-
pendently of PDE inhibition. Glucocorticoids can also inhibit 
uptake of ß-adrenergic receptor (ßAR) agonists by cells42 but 
our assays are performed in cultured cells with no other drugs 
or serum present. In these conditions, glucocorticoids would 
not increase cAMP within seconds via inhibition of uptake of 
other drugs, even if the cells were producing autocrine-acting 
agonists. Glucocorticoids are also known to increase expres-
sion of ßAR43 but this occurs via genomic action so also can't 
explain our observations.
Based on these findings we speculate that these glucocor-
ticoids activate a GPCR of unknown identity. This mecha-
nism appears to be highly conserved through evolution since 
both insect and amphibian genomes appear to contain GPCRs 
that respond to glucocorticoids.9,44 The canonical nuclear GR 
appears to be dispensable for the response as its knockdown 
via siRNA had little effect on these responses.34 RU-486, a 
progesterone and GR antagonist, blocks the non-genomic 
signaling but this chemical likely has the structural ele-
ments needed to antagonize glucocorticoid action at non-GR 
binding sites.34 RU-486 can also stimulate GR responses so 
this chemical can act as both an antagonist and an agonist 
of GR.45,46 GR has been shown to exist in the plasma mem-
brane of various cells.17 Plasma membrane GR could directly 
activate Gαs or may do so via transactivation of a GPCR. 
However, the concentrations required to activate cAMP sig-
naling are much higher than those that activate genomic sig-
naling, implying that these occur via different binding sites. It 
does not appear that glucocorticoids work through binding to 
GPER since two different antagonists had no effect on gluco-
corticoid cAMP responses (Figure 4). More work is needed 
to thoroughly understand the receptor mechanism involved in 
glucocorticoid stimulation of cAMP.
A number of investigators have reported rapid actions of 
glucocorticoids in various cells and tissues. These effects 
include modulation of basal and stimulated intracellular cal-
cium levels, increases in reactive oxygen species and reactive 
nitrogen species, increased inflammatory and apoptotic path-
ways and reduced skeletal and smooth muscle tone (recently 
reviewed in 5). Gαs-cAMP signaling has numerous and diverse 
effects in all cells so many of these prior observations of 
rapid glucocorticoid signaling may be mediated via increased 
cAMP. Efforts to understand the non-genomic effects of 
glucocorticoids have focused on using the membrane- 
impermeable cortisol-BSA conjugate.17,18 However, this 
agent is a weak activator of cAMP signaling (Figure 2F) so 
this is not an optimal approach. Gαs knockdown is a more 
specific and effective intervention that will be a more pow-
erful means for understanding this non-genomic signaling. 
This approach will be useful for understanding the divergent 
actions of glucocorticoids in other cells and tissues (at least 
until the membrane receptor involved is identified).
Other work demonstrates the physiological relevance of 
this non-genomic signaling by glucocorticoids. We demon-
strate that budesonide-stimulated cAMP augments formoterol- 
induced bronchodilation in human small airways when 
combined with formoterol, a long-acting ßAR agonist.34 It 
is interesting to note that in the present study the glucocorti-
coids most efficacious at stimulating cAMP production were 
budesonide and fluticasone, two drugs developed for inhaled 
use in asthma. The clinical utility of these inhaled glucocorti-
coids is clearly enhanced by this unappreciated non-genomic 
signaling that enhances bronchodilation. While success of 
these important drugs may have been aided by this additional 
activity, a complete understanding of this alternate signal-
ing paradigm may inform future development of new drugs. 
Can drugs be designed with different mixtures of genomic 
Gene symbols Gene name
SH3PXD2B SH3 and PX domains 2B
SHISAL1 Shisa Like 1
SLC19A2 solute carrier family 19 (thiamine transporter), 
member 2
SQOR Sulfide Quinone Oxidoreductase




TEF thyrotrophic embryonic factor
TMEM158 transmembrane protein 158 (gene/pseudogene)
ZBTB16 zinc finger and BTB domain containing 16
T A B L E  2  (Continued)
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and non-genomic actions for specific clinical applications? 
Some side effects of glucocorticoids may be dependent on 
one signaling pathway or another, allowing improved drug 
design. Finally, a novel membrane receptor capable of aug-
menting bronchodilation in small airways could provide a 
much-needed alternative drug target to existing ßAR ago-
nists, which suffer from issues with tachyphylaxis and poten-
tial maladaptive responses after long-term use.
Confirmation that glucocorticoids act via both rapid, 
non-genomic, and canonical genomic signaling mechanisms 
led us to ask what the role of each might be in context of the 
known effects of these drugs on the gene transcription. We hy-
pothesized that the cAMP signal serves as a primer to subse-
quent genomic effects, shaping the size, and/or direction of the 
transcription of particular genes. Using RNA-seq and compar-
ing the budesonide treatment transcriptomes from control cells 
and cells with Gαs knockdown allowed identification of the ef-
fects of both the genomic and non-genomic signals. Comparing 
our data to existing data sets demonstrate that the gene expres-
sion changes we observe are highly reproducible across other 
cell types and other glucocorticoids. We identified a panel of 
140 differentially expressed genes that characterize the effects 
of budesonide in HASM. Of these, 94 genes were shared be-
tween the control and Gαs knockdown conditions and 48 were 
unique to the control. These 48 genes (Table 2) depend upon 
the non-genomic cAMP signal for their differential expression 
since they were not significantly altered by budesonide treat-
ment in cells lacking Gαs. Thus, one-third of the genes altered 
by budesonide treatment depended upon the non-genomic 
signal in some way. These results show the importance of this 
alternate signaling mechanism and force a rethinking of how 
glucocorticoids act to alter cell function. We propose that this 
non-genomic site of action is not an off-target effect, but rather 
an integral part of canonical glucocorticoid action.
Our study does have some limitations that require fur-
ther research. In particular, we chose a 24 hours time point 
to study the transcriptional effects of budesonide in order 
to capture the classical genomic effects. A rapid increase in 
cAMP upon adding glucocorticoid to HASMs suggests that 
the non-genomic signaling could begin to alter the transcrip-
tional activity soon after (within an hour or two) glucocor-
ticoid application. Therefore, the transcriptional activity we 
observe at the 24 hours time point may be too late to capture 
the full effect of the non-genomic signaling events. Additional 
studies are needed to capture RNA-Seq datapoints from early 
glucocorticoid treatments to better understand non-genomic 
activity attributed to glucocorticoids. Even with this limita-
tion, our data makes clear that the non-genomic signaling via 
Gαs and cAMP contributes substantially to the regulation of 
certain glucocorticoid-responsive genes. We imagine that the 
non-genomic signal integrates with the genomic signal via 
the convergence of transcription factors regulated by cAMP, 
including but not limited to CREB, with classical GRE at 
the promotor of certain genes (Figure 6). More research is 
needed to understand how these very different signaling mo-
dalities integrate at the level of the gene transcription.
F I G U R E  6  Schematic diagram of 
proposed signaling by a putative membrane 
glucocorticoid receptor (mGR). We 
propose two signaling pathways mediated 
by glucocorticoids, the canonical cytosolic 
GRα receptor mediating direct genomic 
effects via GRE and a second, non-genomic 
activation of Gαs and cAMP signaling 
(illustrated here as signaling via CREB 
for simplicity, but other transcription 
factors are likely involved). The latter 
can have both rapid effects and effects 
that contribute to the genomic actions of 
glucocorticoids
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Our study is also limited to a few cell types (just HASM in 
the case of RNA-seq) so broad conclusions about the relevance 
non-genomic cAMP signaling by glucocorticoids won't be ap-
preciated until other cell types can be studied. However, our 
analysis of the 48 gene non-genomic signature in the existing 
gene expression datasets indicate that many cell types contain 
this signature. It will be of particular importance to understand 
how immune cells, major targets of glucocorticoid therapy, 
respond in terms of both genomic, and non-genomic signal-
ing. The concentrations required for glucocorticoids to induce 
cAMP signaling are higher than those associated with activa-
tion of nuclear glucocorticoid receptors. While this highlights 
that a different receptor may be involved, one might question 
the clinical relevance of the glucocorticoid concentrations we 
use. While local tissue concentrations of budesonide following 
inhalation dosing are difficult to determine, plasma concen-
trations of glucocorticoid following oral dosing of 80 mg in 
humans reaches peaks of nearly 4 µM.47 Thus, the responses 
we observe are relevant to therapeutic uses of glucocorticoids.
Our study identifies a rapid, non-genomic signaling 
mechanism by glucocorticoids that contributes to the known 
gene expression changes induced by these drugs. By acting 
on a membrane receptor and stimulating Gαs, glucocorticoids 
increase the cAMP levels in cells within seconds. We hypoth-
esize that these signals get integrated into the networks that 
alter the expression of many genes along with the canonical 
genomic signaling by nuclear GR. This non-genomic signal 
can also contribute to rapid effects such a smooth muscle re-
laxation and likely many others. These findings help explain 
the clinical utility of inhaled glucocorticoids on an acute 
basis but also provide a specific mechanism that can be lev-
eraged for the development of future glucocorticoid analogs.
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 Supplemental Figure 1:  Venn diagram showing the overlap of differentially expressed genes 
due to budesonide 24-hour treatment in (1) control, (2) Gas knockdown (kd) HASM, and (3) 
dexamethasone 18-hour treatment in control HASM published by Himes et al. 2014. 
 Supplemental Figure 2: Unsupervised Hierarchical clustering of log2(TPM) gene expression of 
48 genes unique in budesonide signature compared to Gas-knockdown budesonide signature 
captures budesonide-specific transcriptional activity in HASM. Dendrograms represent the 
hierarchical clustering based on the Euclidean distance between two gene expression values or 
two samples. 26 of the 48 genes are overexpressed with budesonide treatment. Darker red 
indicates higher expression, and darker blue indicates lower expression.   
 
 
Supplemental Figure 3: Top 10 ranked connectivity scores, quantitative scores between a 
query gene-list and a perturbagen in nine cell lines. Members of glucocorticoid agonists had 
high connectivity score when 48 genes unique to budesonide’s Gas-dependent gene expression 
were queried for similarities and dissimilarities against more than a million gene expression 
signatures in ConnectivityMap (CMap), a publicly available database. 
  
  
Supplemental Figure 4: Predicted budesonide activities using both budesonide (genomic + 
non-genomic) and budesonide Gas knockdown (genomic only) signatures were significantly 
correlated (r=0.9977, p-value < 0.0001). 
  
Supplemental Table 1: Predicted budesonide activity using budesonide (genomic + non-
genomic) and budesonide Gas knockdown (genomic only) signatures in 34 Human Airway 









signature (genomic  
+ non-genomic)  
Budesonide 
activity signature 
(genomic  only)  
GSM2473333  asthma   budesonide 0.98 0.96 
GSM2473339  asthma   budesonide 0.86 0.94 
GSM2473344  asthma   budesonide 0.97 0.98 
GSM2473345  asthma   budesonide 0.97 0.99 
GSM2473350  asthma   budesonide 0.96 0.96 
GSM2473354  asthma   budesonide 0.98 0.99 
GSM2473355  asthma   budesonide 0.97 0.94 
GSM2473361  asthma   budesonide 0.98 0.99 
GSM2473366  asthma   budesonide 0.98 0.98 
GSM2473337  non_asthma   budesonide 0.97 0.96 
GSM2473340  non_asthma   budesonide 0.98 0.98 
GSM2473341  non_asthma   budesonide 0.98 0.98 
GSM2473349  non_asthma   budesonide 0.98 0.98 
GSM2473351  non_asthma   budesonide 0.98 0.99 
GSM2473359  non_asthma   budesonide 0.94 0.97 
GSM2473362  non_asthma   budesonide 0.99 0.99 
GSM2473363  non_asthma   budesonide 0.98 0.98 
GSM2473334  asthma   vehicle 0 0 
GSM2473335  asthma   vehicle 0 0 
GSM2473336  asthma   vehicle 0 0 
GSM2473346  asthma   vehicle 0 0 
GSM2473347  asthma   vehicle 0 0 
GSM2473348  asthma   vehicle 0 0 
GSM2473356  asthma   vehicle 0 0 
GSM2473357  asthma   vehicle 0 0 
GSM2473358  asthma   vehicle 0 0 
GSM2473338  non_asthma   vehicle 0 0 
GSM2473342  non_asthma   vehicle 0 0 
GSM2473343  non_asthma   vehicle 0 0 
GSM2473352  non_asthma   vehicle 0 0 
GSM2473353  non_asthma   vehicle 0 0 
GSM2473360  non_asthma   vehicle 0 0 
GSM2473364  non_asthma   vehicle 0 0 




Supplemental Table 2: Ranked connectivity scores (CS) for highly similar (>95) and dissimilar 
(<-95) gene expression against more than 1.7 million perturbation samples in CMAP database 





98.97 Glucocorticoid receptor agonist - 
98.84 dexamethasone Glucocorticoid receptor agonist 
98.77 fluocinolone Glucocorticoid receptor agonist 
98.59 fluorometholone Glucocorticoid receptor agonist 
98.56 tacrolimus Calcineurin inhibitor 
98.13 halometasone Glucocorticoid receptor agonist 
98.06 mometasone Glucocorticoid receptor agonist 
97.96 clobetasol Glucocorticoid receptor agonist 
97.65 fluocinonide Glucocorticoid receptor agonist 
97.59 betamethasone Glucocorticoid receptor agonist 
97.57 methylprednisolone Glucocorticoid receptor agonist 
97.42 fludroxycortide Glucocorticoid receptor agonist 
97.32 alclometasone Glucocorticoid receptor agonist 
97.29 megestrol progesterone receptor agonist 
97.24 beclometasone Glucocorticoid receptor agonist 
97.08 fluticasone Glucocorticoid receptor agonist 
97.08 L-690330 Inositol monophosphatase inhibitor 
97.04 flumetasone Glucocorticoid receptor agonist 
96.97 hydrocortisone Glucocorticoid receptor agonist 
96.97 RHO-kinase-inhibitor-III[rockout] Rho associated kinase inhibitor 
96.9 desoximetasone Glucocorticoid receptor agonist 
96.79 triamcinolone Glucocorticoid receptor agonist 
96.62 tropisetron Serotonin receptor antagonist 
96.62 hydrocortisone Glucocorticoid receptor agonist 
96.58 hydrocortisone Glucocorticoid receptor agonist 
96.09 fluticasone Glucocorticoid receptor agonist 
95.77 budesonide Glucocorticoid receptor agonist 
95.55 halcinonide Glucocorticoid receptor agonist 
95.14 rimexolone Glucocorticoid receptor agonist 
-96.81 PJ-34 PARP inhibitor 
 
